针对性治疗对生物标志物的作用的子组识别,用于时间到事件数据
Gajendra K Vishwakarma1, Atanu Bhattacharjee2, Fatih Tank3
1Department of Mathematics and Computing.
Cancer biomarkers : section A of Disease markers
|November 19, 2023
概括
本研究介绍了基于生物标志物的瘤学试验的统计方法,使用分子向剂 (MTA) 数据来识别患者亚组并提高癌症治疗的有效性.
科学领域:
- 在瘤学瘤学.
- 生物统计学 生物统计学
- 临床试验设计 临床试验设计
背景情况:
- 生物标志物驱动的试验已经改变了瘤药物开发,超越了传统的分阶段方法进行篮子研究.
- 用向抑制剂治疗非小细胞肺癌 (NSCLC) 的成功需要将这种范式扩展到其他癌症类型.
研究的目的:
- 开发生物标志物驱动的瘤学试验的统计方法.
- 探索分子向剂 (MTA) 的剂量反应建模和时间到事件算法.
- 模拟MTA事件时间数据中的子组识别.
主要方法:
- 在MTA数据上利用剂量反应建模和时间到事件算法.
- 采用马尔科夫链蒙特卡洛 (MCMC) 技术和贝叶斯方法通过值限值 (TLV) 进行子集选择.
- 进行了模拟研究来分析MTA的时间到事件数据.
主要成果:
- 观察到的MTA值在12-16的范围内,预计治疗前后水平的边际偏移.
- 考克斯的时间变化模型被提议用于建立MTA和生存时间之间的因果关系.
- 开发统计方法来支持在瘤学研究中的生物标志物驱动试验.
结论:
- 扩展生物标志物驱动的试验应用超越NSCLC到其他癌症部位.
- 证明了使用MTA作为预测生物标志物的可行性和有效性.
- 奠定了改进和验证临床试验中生物标志物使用的基础,以提高精准医学.
相关概念视频
Comparing the Survival Analysis of Two or More Groups
199
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
199
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Cancer Survival Analysis
356
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
356
Kaplan-Meier Approach
153
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
153
Introduction To Survival Analysis
247
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
247
Hazard Ratio
134
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
134


